Literature DB >> 27577869

NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.

Nathalie K Zgheib1, Reem Akika1, Rami Mahfouz2, Carol Al Aridi3, Khaled M Ghanem3, Raya Saab3, Miguel R Abboud3, Nidale Tarek3, Hassan El Solh3, Samar A Muwakkit3.   

Abstract

BACKGROUND: Interindividual variability in thiopurine-related toxicity could not be completely explained by thiopurine S-methyltransferase (TPMT) polymorphisms, as a number of patients who are homozygous wild type or normal for TPMT still develop toxicity that necessitates 6-mercaptopurine (MP) dose reduction or protocol interruption. Recently, few studies reported on an inherited nucleoside diphosphate-linked moiety X motif 15 (NUDT15) c.415C>T low-function variant that is associated with decreased thiopurine metabolism and leukopenia in childhood acute lymphoblastic leukemia (ALL) and other diseases. PROCEDURES: The aim of this study is to measure the frequency of TPMT and NUDT15 polymorphisms and assess whether they are predictors of MP intolerance in children treated for ALL. One hundred thirty-seven patients with ALL of whom 121 were Lebanese were evaluated. MP dose intensity was calculated as the ratio of the tolerated MP dose to planned dose during continuation phase to maintain an absolute neutrophil count (ANC) dose above 300 per μl.
RESULTS: One patient was NUDT15 heterozygous TC and tolerated only 33.33% of the planned MP dose, which was statistically significantly different from the median-tolerated MP dose intensity of the rest of the cohort (76.00%). Three patients had the TPMT*3A haplotype and tolerated 40.00-66.66% of the planned MP dose, which was also statistically significantly different from the rest of the cohort.
CONCLUSIONS: This is the first report on the association of TPMT and NUDT15 polymorphisms with MP dose intolerance in Arab patients with ALL. Genotyping for additional polymorphisms may be warranted for potential gene/allele-dose effect.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  6-mercaptopurine; NUDT15; TPMT; acute lymphoblastic leukemia

Mesh:

Substances:

Year:  2016        PMID: 27577869     DOI: 10.1002/pbc.26189

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  17 in total

1.  Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia.

Authors:  Yue Zhou; Li Wang; Xiao-Ying Zhai; Li Wen; Fang Tang; Fan Yang; Xi-Ting Liu; Lei Dong; Li-Juan Zhi; Hai-Yan Shi; Guo-Xiang Hao; Yi Zheng; Evelyne Jacqz-Aigrain; Tian-You Wang; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

Review 2.  [Significance of NUDT15 gene in individualized treatment with 6-mercaptopurine in children with acute lymphoblastic leukemia].

Authors:  Jing He; Ling Liu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-01

3.  Pharmacogenomics in Children.

Authors:  Michael J Rieder; Abdelbaset A Elzagallaai
Journal:  Methods Mol Biol       Date:  2022

4.  Childhood acute lymphoblastic leukemia mercaptopurine intolerance is associated with NUDT15 variants.

Authors:  Der-Shiun Wang; Chih-Hsiang Yu; Chien-Yu Lin; Ya-Hsuan Chang; Kai-Hsin Lin; Dong-Tsamn Lin; Shiann-Tarng Jou; Meng-Yao Lu; Hsiu-Hao Chang; Shu-Wha Lin; Hsuan-Yu Chen; Yung-Li Yang
Journal:  Pediatr Res       Date:  2020-03-27       Impact factor: 3.756

5.  Diplotype analysis of NUDT15 variants and 6-mercaptopurine sensitivity in pediatric lymphoid neoplasms.

Authors:  Shinichi Tsujimoto; Tomoo Osumi; Meri Uchiyama; Ryota Shirai; Takaya Moriyama; Rina Nishii; Yuji Yamada; Ko Kudo; Masahiro Sekiguchi; Yuki Arakawa; Masanori Yoshida; Toru Uchiyama; Kiminori Terui; Shuichi Ito; Katsuyoshi Koh; Junko Takita; Etsuro Ito; Daisuke Tomizawa; Atsushi Manabe; Nobutaka Kiyokawa; Jun J Yang; Motohiro Kato
Journal:  Leukemia       Date:  2018-07-02       Impact factor: 11.528

6.  NUDT15 R139C variation increases the risk of azathioprine-induced toxicity in Chinese subjects: Case report and literature review.

Authors:  Xiang Fei; Qing Shu; Bing-Zhu Hua; Shi-Ying Wang; Zhi-Yong Chen; Wei-Hong Ge; Yun Fang
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

7.  Characterization of pharmacogenetic markers related to Acute Lymphoblastic Leukemia toxicity in Amazonian native Americans population.

Authors:  Darlen Cardoso de Carvalho; Alayde Vieira Wanderley; André Mauricio Ribeiro Dos Santos; Fabiano Cordeiro Moreira; Roberta Borges Andrade de Sá; Marianne Rodrigues Fernandes; Antonio André Conde Modesto; Tatiane Piedade de Souza; Amanda Cohen-Paes; Luciana Pereira Colares Leitão; Juliana Carla Gomes Rodrigues; Artur Luiz da Costa da Silva; João Farias Guerreiro; Sidney Santos; André Salim Khayat; Paulo Pimentel de Assumpção; Ney Pereira Carneiro Dos Santos
Journal:  Sci Rep       Date:  2020-06-24       Impact factor: 4.379

8.  NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases.

Authors:  Toshiyuki Sato; Tetsuya Takagawa; Yoichi Kakuta; Akihiro Nishio; Mikio Kawai; Koji Kamikozuru; Yoko Yokoyama; Yuko Kita; Takako Miyazaki; Masaki Iimuro; Nobuyuki Hida; Kazutoshi Hori; Hiroki Ikeuchi; Shiro Nakamura
Journal:  Intest Res       Date:  2017-06-12

9.  Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?

Authors:  Hong Zhou; Lei Li; Peng Yang; Lin Yang; Jin E Zheng; Ying Zhou; Yong Han
Journal:  BMC Cancer       Date:  2018-05-02       Impact factor: 4.430

10.  Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis.

Authors:  Liang Chen; Huai-Xiu Yan; Xiao-Wei Liu; Wen-Xin Chen
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.